NGS demonstrates improved disease monitoring in acute lymphoblastic leukaemia, indicating its clinical utility for B-cell patients.
Background: Next-generation sequencing (NGS)-based measurable residual disease (MRD) testing is increasingly adopted in routine patient care for acute lymphoblastic leukaemia (ALL). We have successfully implemented NGS-based MRD testing since 2018 and demonstrated its clinical utility in B-cell acute lymphoblastic leukaemia (B-ALL).
No takes yet. Share an insight, caveat, or question.
Le et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: